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Abstract
In this study, we analysed the possible influence of the c.419-43delT BMPR2 variant in patients with Graves’ disease (GD), in a molecular basis,
focusing our efforts on possible alterations in the mRNA processing and synthesis. The molecular assessment of this variant in patients with
GD would shed light on the association between the BMPR2 gene and the disease. The variant was detected in 18%, 55% and 10% of patients
with pulmonary arterial hypertension, GD and in general population, respectively. Patients with GD fold change showed increased BMPR2
expression when matched against the controls, with a mean of 4.21  1.73 (P = 0.001); BMPR2 was overexpressed in the analysed cell cycle
stages. Fold change analysis of variant carriers and non-carriers showed slight overexpression and differences between phases, but none of
them were statistically significant. BMPR2 expression was confirmed in the lymphoblastoid cell lines (LCLs) with a molecular weight of 115 kD,
and no differences between variant carriers and non-carriers were detected. To conclude, the BMPR2 variant c.419-19delT appears in high fre-
quency in patients with GD, and independently of its presence, BMPR2 is overexpressed in the LCLs from the GD patients tested. This increase
could be paired with the described decreased expression of transforming growth factor-b1 in thyroid tissue from patients with GD.
Keywords: pulmonary arterial hypertension Graves’ disease BMPR2 functional analysis lymphoblastoid cell
lines Epstein–Barr virus expression assay TGF-b/BMP
Introduction
The BMPR2 gene (OMIM #600799) is located in the chromosome 2
position q33, and it encodes for the bone morphogenetic protein
receptor of type 2 (UNIPROT #Q13873), a constitutively active serine/
threonine kinase receptor that plays a major role in the transforming
growth factor beta (TGF-b; UNIPROT #P01137) superfamily regula-
tion [1, 2]. Mutations in the germinal line of BMPR2 have been widely
related to at least 50% of the familial cases and 40% of the idiopathic
of pulmonary arterial hypertension (PAH; OMIM #178600, ORPHA
422) [1, 3–6]. Although PAH shows a reduced penetrance pattern,
only 20% of the mutation carriers end up developing the disease [7].
Pulmonary arterial hypertension is a rare disease characterized by
precapillary pulmonary arteries remodel resulting in loss of perme-
ability and increased blood flow resistance that eventually leads to
right heart failure [8–10]. PAH has an annual incidence between 1
and 2 cases per million [11], and in the Spanish population, it has an
incidence between 1.2 and 3.2 and a prevalence between 4.6 and 16
cases per million [12], affecting between two and four times more
women than men [13, 14]. Average age of diagnosis is about
45 years [15], even though symptoms may appear at any age [8].
PAH can be classified as idiopathic (IPAH), familial (FPAH) or associ-
ated with other diseases such as connective tissue diseases, congeni-
tal heart diseases, portal hypertension and drug or toxin exposure
(APAH) [9, 14]. Besides, several cases of associated PAH to GD have
been reported [16–18].
After BMPR2 screening in PAH patients, we detected the c.419-
43delT mutation in several of them [5]. Whenever we start to study a
new mutation, a population analysis is carried out using DNA samples
from general population and patients that have given their consent for
the usage and storage of their anonymized genetic material by our
group in future projects. We found this variant with a frequency up to
a 40% in a series of samples from an investigation project on thyroid
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autoimmunity from the Endocrinology Service of the Complexo
Hospitalario Universitario de Vigo.
These findings lead us to analyse the whole set of samples from
that project which consisted in GD patients samples. GD is one of the
most common autoimmune disorders, with an annual incidence of
approximately 21 new cases per 100,000 individuals [19], affecting
mostly women with a 5:1 ratio [20]. Clinical presentation of the GD is
characterized by thyrotoxicosis, goitre and ophthalmopathy. Although
the only common sign between every patient is the hyperthyroidism
[21] caused by antibodies that imitate the action of the thyroid-stimu-
lant hormone (TSH; UNIPROT #P01222) activating its receptor. As an
autoimmune disorder, GD has a variety of associated pathologies,
being the APAH diagnosed in about a 15% of the cardiopathies
caused by GD [16, 18].
Genetic variants are constantly reported, relying on in silico analy-
sis for the prediction of its pathogenicity. These kind of predictions
often differ from reality, where missense, synonymous or intronic
mutations can end up playing an important role in the development of
a disease. Synonymous and non-synonymous can alter protein struc-
ture, the splicing process and mRNA stability and conformation.
There are several examples in the literature showing pathogenic
mutations where the in silico analysis came back negative [3, 7, 22].
The functional studies are of great value to investigate the role of
these mutations in the development of a disease.
The objectives of this work were to assess the presence of the
c.419-43delT variation in patients with GD and to analyse the func-
tionality of the mutation by minigene assay for splicing alterations
and quantitative real-time PCR for expression measurement. Func-
tional analysis of this frequent polymorphism in patients with GD
would shed light on the relationship between the BMPR2 gene and
the disease.
Patients and methods
Patients with GD and samples
Graves’ disease patients’ diagnosis was performed based in the laboratory
examination of hyperthyroidism patients showing low or suppressed TSH
and high levels of T3I and T4I. In cases where GD appeared associated
with ophthalmopathy and diffuse goitre, more tests were needed. On the
contrary, complementary tests depending on the centre of diagnosis were
performed, such as autoantibodies against TSH receptor detection (thy-
roid-stimulating immunoglobulin), thyroid scintigraphy or Doppler echog-
raphy. Patients and controls signed an informed consent and the
Autonomic Ethics Committee approved the study (Galician Ethical Com-
mittee for Clinical Research; Comite Autonomico de Etica da Investi-
gacion de Galicia—CAEI de Galicia) followed the clinical-ethical practices
of the Spanish Government and the Helsinki Declaration.
Mutational analysis in BMPR2 gene
Genomic DNA was extracted, using the FlexiGene DNA Kit (Qiagen, Hilden,
Germany), according to manufacturer’s protocol, from peripheral blood.
Genomic DNA amplification was performed with 50 ng of genomic DNA
from each individual with a polymerase chain reaction (PCR), using
GoTaq Green Master Mix (Promega Corporation, Madison, WI, USA).
The primers used to amplify the BMPR2 gene were as described by Deng
et al. [23], and changes in other regions were not analysed. PCR amplifi-
cation was performed at 55°C annealing temperature for the exons 1, 3,
5, 6, 7, 8, 9, 10, 11 and 13 and 60°C for the exons 2 and 12. PCR prod-
ucts were separated by electrophoresis through 2% agarose gels contain-
ing SYBR Safe DNA Gel Stain (Invitrogen, Carlsbad, CA, USA); to confirm
the PCR products, HyperLadder IV (New England Biolabs, Ipswich, MA,
USA) was used as the molecular weight marker; and PCR products were
purified using ExoSAP-IT kit (USB Corporation, Cleveland, OH, USA).
Sequencing reactions were performed using the BigDye Terminator ver-
sion 3.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA, USA),
and the fragments were purified using Agencourt CleanSEQ-Dye Termina-
tor Removal (Beckman Coulter, Brea, CA, USA). A second independent
PCR and sequencing reaction in both the forward and reverse strands
was performed to check for the detected mutations.
Sequences were aligned to the reference Ensembl DNA sequence
[ENST00000374580]. To predict whether changes could affect, create
or eliminate donor/acceptor splice sites were used Neural Network
SPLICE (NNSplice) 0.9 version from the Berkeley Drosophila Genome
Project (Lawrence Berkeley National Laboratory, Berkeley, CA, USA),
NetGene2 (Technical University of Denmark, Kongens Lyngby, Den-
mark), Splice View, Human Splicing Finder 2.4.1 version (Aix Marseille
Université, Marseille, France) and Automated Splice Site Exon Defini-
tion Server-ASSEDA (University of Western Ontario, London, Canada).
Minigene assay
For the c.419delT variant, we amplified the exon and 250 bp of 50and 30
intronic junctions from the control and the GD patient DNA with high-
fidelity Phusion polymerase (Finnzymes, Espoo, Finland) to obtain the
wild-type, with primers carrying restriction sites for XhoI/NheI (New
England Biolabs). The forward and reverse primers were 50-CTCGA
GACTTGGTGTTTTAGTGTTCC-30 and 50-GCTAGCGAAAGGGGTAGTGACT
GATAA-30, respectively. The amplified fragments were cloned using the
T4 DNA ligase concentrated (New England Biolabs) in the Exon Trap-
ping Expression Vector p.SPL3 (Invitrogen, San Diego, CA, USA), pro-
vided by Dr. Jose Marıa Millan. Wild-type and mutant construct were
amplified using the GoTaq Green Master Mix (Promega Corporation)
and were sequenced using the BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Applied Biosystems). The forward and reverse primers were
50-GCCAGGACATGGACCGCACGCTCGA-30 and 50-TCGAGCGTGCGGTCCA
TGTCCTGGC-30, respectively.
As described previously [22], 2 9 105 COS-7 cells (from kidney of
Cercopithecus aethiops, provided by Dr. Jose Marıa Millan) were grown
to 90% confluency in Dulbecco’s modified Eagle medium-DMEM (Gibco,
Grand Island, NY, USA) supplemented with 10% foetal bovine serum
(PAA Laboratories, Pasching, Austria) and L-glutamine penicillin/strepto-
mycin (Gibco) at 37°C and 5% CO2 atmosphere. COS-7 cells were
transiently transfected in triplicates with the minigene constructs using
Lipofectamine 2000 reagents (Thermo Scientific, Carlsbad, CA, USA)
according to manufacturer’s instructions. RNA was extracted and puri-
fied using the Nucleic Acid and Protein Purification kit (NucleoSpin RNA
II; Macherey-Nagel, D€uren, Germany), and cDNA was synthesized using
the GeneAmp Gold RNA PCR Core Kit (Applied Biosystems). Primers
used to amplify the cDNA were 50-TCTGAGTCACCTGGACAACC-30 and
50-ATCTCAGTGGTATTTGTGAGC-30, using the high-fidelity Phusion
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polymerase (Finnzymes). PCR products were analysed in 2% agarose
gels containing SYBR Safe DNA Gel Stain (Invitrogen) and, finally, by
direct sequencing in both senses.
Generation of LCLs by infection with
Epstein–Barr virus
To obtain enough cells for gene expression from both controls and
patients, immortalization of B cells and generation of LCLs was per-
formed by infection with Epstein–Barr virus (EBV)-containing culture
media, obtained from exponentially growing tetradecanoyl phorbol acet-
ate-stimulated B95-8 cells (Prof. Mark Peakman, Department of
Immunobiology, King’s College School of Medicine). Supernatants were
stored at 20°C until usage.
To obtain LCLs, peripheral blood mononuclear cells (PBMCs) from
both controls (n = 8) and GD patients (n = 7) were cultured in 25-cm2
tissue culture flasks, treated for 1 hr with FK-506 (Tacrolimus; Sigma-
Aldrich, Madrid, Spain) to inhibit the expansion of T lymphocytes and
infected with EBV-containing culture media. After 5–7 days, clusters of
transformed cells were detected, and culture media were changed every
2–3 days since then as required until enough cells were available for
both cell characterization and gene expression analysis. Cellular origin
of the growing cells was determined by cell staining using anti-CD19
antibodies (BD Biosciences, Madrid, Spain) and flow cytometry analysis
(BD FACScalibur, BD Biosciences, Madrid, Spain). Phenotypic analysis
was performed by duplicates using cells obtained 5–7 days apart, to
analyse the stability of the phenotype. CD19 expression was performed
after gating cells in the forward-scatter lymphocyte region.
Sorter and collected cells
Cells from the controls and patients with GD were cultured in a medium
consisting in RPMI 1640 Medium (Gibco, Carlsbad, CA, USA). Cultures
were stained with Hoechst 33342 (BD Biosciences) following the manu-
facturer’s recommendations. Thereafter, cells were harvested and resus-
pended at a concentration of 1 9 106/ml in sort buffer + 2 mM EDTA
and DNAse and then sorted base on the DNA content. Cells in G0/G1, S
and G2/M were collected using a BD Biosciences FACS Aria III flow
cytometer (BD Biosciences, Madrid, Spain). BD FACSDiva v8.0.1 (BD
Biosciences, Madrid, Spain) and Flowjo v7.6.5 (FlowJo, LLC, Ashland,
OR, USA) were used to data analysis. Then, the recollected cells were
resuspended in RNAlater solution from Ambion (Invitrogen) and were
stored at 80°C.
cDNA synthesis and expression assay by
quantitative real-time PCR
A total of 2 lg of total RNA was used to perform the cDNA synthesis with
the GeneAmp RNA PCR Core Kit (Life Technologies, Carlsbad, CA, USA).
The cDNA was later used to amplify the target gene (BMPR2) and the ref-
erence genes (GADPH and ACTB) by quantitative real-time (qPCR) using
commercial Taqman probes, with 4331182, 4331182 and 4331182 refer-
ences, respectively (Life Technologies). The reaction was carried out in a
Step One thermocycler (Life Technologies) with a total amount of 50 ng
of cDNA in 20 ll, containing 10 ll of Taqman Universal PCR Mastermix
(Life Technologies) and 1 ll of Taqman Gene Expression Mix (Life Tech-
nologies). The amplification conditions were as follows: 50°C for 2 min.,
95°C for 10 min. and 40 cycles of 15 sec. at 95°C and 1 min. at 60°C.
Expression data normalization was carried out using the Hellemans 2007
method [24] to calculate the normalized relative quantities (NRQ) and the
fold change for the intergroup comparison.
Confirmation of the BMPR2 Protein expression by
Western blot
Western blot analysis was performed using 20 lg of protein obtained
from LCLs and cultured B lymphocytes. Laemmli sample buffer (Bio-Rad,
Hercules, CA, USA) containing 5% b-mercaptoethanol was used to dilute
the samples before heating them at 95°C for 5 min. Proteins were sepa-
rated by SDS-PAGE using a 7.5% TGX Mini-Protean precast gel (Bio-
Rad). After electrophoresis, protein transfer into a PVDF membrane was
performed using the Transfer Blot Turbo Transfer Pack (Bio-Rad) in a
semidry blotting apparatus (Bio-Rad) for 7 min. at 1.3 A. The membrane
was then blocked for 1 hr at room temperature using 5% non-fat milk in
Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBST). The
immunoblotting was performed incubating the membrane overnight at
4°C with mouse monoclonal anti-BMPR2 IgG (reference Ab130206;
ABCAM, Cambridge, UK) diluted 1/250 in blocking solution. After washing
with blocking solution for 3 times, the membrane was incubated with 1/
15,000 dilution of rabbit antimouse IgG conjugated with horseradish per-
oxidase (reference A9044; Sigma-Aldrich, St. Louis, MO, USA) for
45 min. in blocking solution. TBS was then used to wash the membrane.
BMPR2 was detected by chemiluminescence using the Clarity
Western ECL Substrate (Bio-Rad) in a ChemiDoc™ (Bio-Rad) digital
camera-based imaging system. Loading control was performed by Coo-
massie Brilliant Blue (R-250) staining as described by Welinder and
Ekblad in 2010 [25].
Statistical analysis
Statistical analysis was carried out using the IBM-SPSS v.19 software
(IBM, Armonk, NY, USA) and GraphPad Prism (GraphPad Software INC,
La Jolla, CA, USA). Nonparametric statistic tests were used for
intragroup analysis (Kruskal–Wallis and Wilcoxon) and intergroup
(Mann–Whitney). Probability values of less than 0.05 were considered
statistically significant.
Results
Controls and GD patient samples
Eight controls, obtained from the Faculty of pharmacy of University of
Santiago de Compostela, seven patients with GD, obtained from the
Endocrine, Diabetes, Nutrition and Metabolism Department of Com-
plexo Hospitalario Universitario de Vigo and 100 individuals from gen-
eral population, obtained from Complexo Hospitalatio Universitario de
Vigo, were included in this analysis. Four of the controls were women,
and four were men; their medical history and analytics showed that
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all values were within normal parameters, and no chronic pathologies
nor hyperthyroidism/hypothyroidism were detected either. However,
all patients with GD included in this study were women. The clinical
characteristics of GD patients are summarized in Table 1.
For this analysis, we have differentiated between individuals from
general population and controls. The first group represents random
Galician population that did not have their medical history checked;
their samples were only used to assess the frequency of the polymor-
phism in population from the same area as the patients. While, as sta-
ted above, controls were tested to assure the absence of health
conditions that could jeopardize the results.
Mutational frequency of the BMPR2 gene in
controls, GD patients and general population
We checked c.419-43delT variant, in BMPR2 gene, in 57 patients with
PAH, in 40 patients with GD and in 100 individuals from general
population, found the deletion in 18% of patients with PAH, in 55% of
patients with GD and in 10% of individuals from general population
(Fig. 1). Moreover, after the mutational analysis of BMPR2 gene in
the controls we did not find variants in exons and intronic junctions
nor in 50UTR region. However, in three the seven analysed GD
patients we identified the c.419-43delT variant.
After the in silico analysis of c.419-43delT, the splicing tools had
foretold the benign nature of this deletion. Besides, we did not find
alterations in the RNA processing using the minigene assay for the
c.419-43delT variant in BMPR2 gene in comparison with the wild-type
sequence, and the results showed that this deletion did not generate a
new transcript (Fig. 2). In addition, we checked the splicing process
using RNA from LCLs and the results were the same as in the
minigene assay.
Phenotypic characterization of LCLs
Growing cells were characterized by flow cytometry after staining with
anti-CD19 monoclonal antibodies. All growing LCLs obtained from
both controls and GD patients were CD19-positive confirming their B-
cell origin. LCLs obtained from controls were almost all CD19 posi-
tive, and this percentage remained stable with time (97.2  1.4% in
the first analysis and 97.7  1.5% in the second analysis)
(mean  SD); when a similar procedure was carried out using
PBMCs obtained from patients with GD, very similar results were
obtained compared to those from controls (95.6  2.1 in the first
analysis and 95.3  2.2 in the second analysis) (mean  SD). These
data confirm the B-cell origin of the growing cell lines obtained from
both controls and GD patients and also the stability of the cell pheno-
type with time.
Cell separation went as expected, obtaining a higher number of
cells for the G0/G1 phase. After sorting the LCLs using the BD Bio-
sciences FACS Aria III flow cytometer (BD Biosciences). For the con-
trol samples, 500,000 cells were isolated for the G0/G1 phase and S
phase and 100,000 cells for the G2/M phase. Same numbers were
obtained for the patients group, with GD, for G2/M phase, and were
isolated 250,000 cells for G0/G1 and S phases.
Table 1 Clinical features of GD patients included in this study
GD patients Gender Age at diagnosis Ophthalmopathy Goitre TSI Thyroid scintigraphy Doppler echography
1 Female 31 Positive Diffuse Positive Hypercaptation ND
2 Female 53 Negative Diffuse Positive Hypercaptation ND
3 Female 33 Positive Diffuse Positive Hypercaptation ND
4 Female 42 Negative Diffuse Negative Hypercaptation ND
5 Female 73 Negative Nodular Positive ND ND
6 Female 56 Positive Diffuse Positive ND ND
7 Female 72 Negative Nodular Positive Hypercaptation ND
GD, Graves’ disease; TSI, thyroid-stimulating immunoglobulin; ND, not determined.
Fig. 1 Percentage of the c.419-43delT variant in pulmonary arterial
hypertension (PAH), Graves’ disease, general population and controls.
An 18% of PAH patients carried this deletion and a 55% of patients
with Graves’ disease carried this variant too. However, the variant was
only present in a 10% of general population and none of our controls
carried it.
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Expression assay of the BMPR2 gene in LCLs
BMPR2 gene expression for patients with GD was detected with a
mean threshold cycle (CT) value of 34.38  2.04 (mean  SD). In
controls, the mean CT was 34.05  0.94. NRQ values for controls
showed similar expression levels between G0/G1 and S with a slight
decrease in G2/M. However, patients with GD G0/G1 and G2/M phases
had similar values, while S phase showed a noticeable drop. These
intragroup differences were not statistical significant. The fold change
obtained after comparing the controls and the patients with GD
showed a generalized increase of expression for the patients
(Fig. 3A), each dot representing individual data compared against the
opposite group (controls and GD patients), showing a mean value of
4.21  1.73 and a median value of 3.71. The increased BMPR2
expression was detected in all the analysed cell cycle phases
(Fig. 3B), and G0/G1 and G2/M phases showed mean fold values of
5.03  3 and 4.75  1.94, and median values of 3.84 and 4.83,
respectively, S phase showed a mean fold increase of 2.93  1.56
and a median of 2.19. These intergroup differences are statistically
significant (P = 0.001).
The GD patients group can be spliced between wild-type and poly-
morphism carriers, and polymorphism carriers showed a mean CT of
34.6  1.99 for BMPR2 detection while the wild-type had a value of
34.08  2.16. NRQ values for wild-type showed the lowest expres-
sion levels in the G0/G1 phase, an slight increase in S, and its maxi-
mum levels in the G2/M. Carriers showed slightly superior NRQ
values than the WT in all phases, with similar levels in the G0/G1 and
S phases and a slight increase in the G2/M, these differences were
not statistical significant. The fold change obtained from these groups
comparison resulted in greater expression for carriers (Fig. 4A), with
a mean value of 1.36  0.47 and a median of 1.28. This slight over-
expression showed greater fold levels in the G0/G1 phase with a mean
value of 2.72  1.69 and a median of 1.62, a slight decrease in the S
phase with 0.78  0.36 mean value and a median of 0.62; and equal
levels for G2/M with mean values of 1.03  0.41 (Fig. 4B) and
median of 1.18.
Fig. 2 Functional analysis of c.419-43delT
variant by minigene assay. (A) Represen-
tative sequence electropherograms for the
c.419-43delT variant in BMPR2 gene. (B)
Sequencing results for in vitro mRNA pro-
cessing for c.419-43delT variant. (C)
Agarose gel electrophoresis shows the
band pattern of the transcripts obtained
after mRNA processing for c.419-43delT
variant. (D) Representative mRNA pro-
cessing for c.419-43delT variant. The vari-
ant produced unchanged splicing when
comparing wild-type and mutant.
Fig. 3 Expression assay results of Graves’ disease (GD) patients and con-
trols. (A) Dot plot representing the fold change between GD patients and
controls without taking into account cell cycle stage. The data showed
augmented expression for the patients with GD when compared against
the controls, and these data are statistically significant (P = 0.001). (B)
Dot plot representing the fold change between GD patients and controls
taking into consideration cell cycle stage. The data showed increased gene
expression for the patients in all the cell cycle stages, and there were no
statistically significant differences between stages.
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Expression confirmation of the BMPR2 protein by
Western blot assay in LCLs
BMPR2 was detected in the positive control (H1299 cell line, lane 1)
and the lymphoblastoids samples matching its predicted molecular
weight of 115 kD, both in the c.419-43delT (lane 2) and the wild-type
sample (lane 3). These results are shown in Figure 5.
Discussion
The advances in mutations’ detection methods offer us high amounts
of data about the changes that we can find in the population, although
there are not yet reliable systems that allow the determination of
mutations’ pathogenicity nor of those variants that may have an
uncertain significance [26]. Thus, when a SNP is detected in high fre-
quency in specific populations, pathology linkage should be consid-
ered, taking into account the enormous rate of variant’s
reclassification [27]. Assessing the functionality of the identified
mutations is especially important in rare diseases, where it has gained
relevance in the last years, as it enhances our ability to correctly iden-
tify pathologies or even gives us the possibility of predicting some-
thing as valuable as patient’s prognosis. Therefore, functional
characterization of gene variants reduces the difficulty of correctly
cataloging them [28, 29] and helps in the task of creating more
accurate bioinformatic applications.
The c.419-43delT variant is relatively common in the European
population, where it has a frequency of 12.7% by ExAc and an
11.7% by Ensembl that when subdivided into the Iberian population
lowers to an 8.4%. In our case, this variant was found in 18% of
the PAH patients analysed, a proportion bigger than the expected
after checking the SNPs databases, but this data were diminished
after we found the polymorphism in 55% of the GD patients anal-
ysed. These data may indicate that the variant in study displays
higher implication than expected in both PAH and GD that was still
unknown. In addition, our analysis of the c.419-43delT variant in
controls and general population supported the described frequen-
cies in different databases.
In this study, we hypothesize that the variant c.419-43delT,
classified as a polymorphism after an exhaustive in silico analysis,
might have an influence in patients diagnosed with GD. Schleinitz
et al. had only previously studied this variant in a cohort, where
they analysed the role of BMPR2 gene in the pathophysiology of
obesity, and no genotype/phenotype correlation was established for
this variant [30]. The high frequency found in our study lead us to
believe about a possible linkage with GD. GD is defined as a multi-
factorial disorder, being caused by a complex interaction between
genotype and environment, which would lead to the loss of toler-
ance against the thyroid antigens, and therefore, being the first
step of immune response against the thyroid gland [21]. In several
families with recurrent autoimmune thyroiditis, there has been
described a positive linkage between GD and various genes that
can be divided among immune system regulators (human leukocyte
Fig. 4 Expression assay results of c.419-43delT carriers and wild-type
patients. (A) Dot plot representing the fold change between carriers and
wild-type patients without taking into consideration cell cycle stage. The
results showed a slight increase in the variant carriers’ BMPR2 expres-
sion, and these data were not statistically significant. (B) Dot plot repre-
senting the fold change between variant carriers and wild-type patients
taking into account cell cycle stage. Data showed a rise of gene expres-
sion in the G0/G1 and a slight decrease for S phase for the carriers,
while in the G2/M, it showed almost identical expression between both
groups. There were no statistically significant differences between
stages.
Fig. 5Western blot results for BMPR2. Expression of the BMPR2 pro-
tein was confirmed in both, variant carriers (lane 2) and non-carriers
(lane 3), to confirm the qPCR results and assess that the protein
molecular weight was correct, no further measurements were
performed.
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antigen—antigen D regulated, HLA-DR; cytotoxic T-lymphocyte-
associated protein4, CTLA4–OMIM #123890; cluster of differentia-
tion 40, CD40—OMIM #109535; and protein tyrosine phosphatase
non-receptor type 22, PTPN22—OMIM #600716) and thyroid speci-
fic (thyroglobulin, TG—OMIM #188450; and thyroid-stimulating
hormone receptor, TSHR–OMIM #603372) had been established,
showing reduced penetrance [31].
After performing the minigene assay for the c.419-43delT variant
to verify its pathogenicity in vitro, we did not find any differences
concerning transcript processing between wild-type and mutant con-
structions, as this variant is not located in a consensus splicing
region [32]. Likewise, we performed functional studies, using lym-
phoblastoid mRNA from carrier patients and patients without the
deletion to confirm the minigene assay results. The mRNA analysis
using lymphoblastoids did not detect any change in the splicing pro-
cess. However, the splicing effect is tissue dependent; thus, these
results should be taken carefully as they have to be confirmed using
vascular endothelial cells or thyroid gland cells [22].
To analyse the expression pattern, we performed qPCR analysis in
PBMCs, with negative results. As circulating B lymphocytes are in the
G0 phase before their activation and beginning of clonal expansion,
we postulated if BMPR2 expression in these cells could be cell cycle
phase dependent. After a literature review, we decided to perform the
EBV immortalization, as the expression of the BMPR2 in these cell
lines had been previously described [7, 33–35].
We found increased expression levels in the patients with GD
when compared against controls, and this overexpression may sup-
port the idea of BMPR2 being related to autoimmunity processes.
Even though when we analysed the expression in the different cell
cycle phases in each group, we did not find significant differences.
This could be explained by the alterations produced by the EBV infec-
tion needed to produce the LCLs, which is able to alter the cell cycle
check points [36]. Increasing the number of samples could be neces-
sary to obtain a significant expression pattern between the cell cycle
phases.
In 2005, Roberts et al. speculated about the possibility of BMPR2
influencing in the development of thyroid pathologies after finding
these kinds of diseases in 100% of the IPAH patients carrying BMPR2
mutations, while only 14% of the non-carriers of BMPR2 mutations
referred these pathologies [37]. More recently, Satoh et al. demon-
strated the existence of increased prevalence and predisposition to
the development of thyroid autoimmune diseases in patients of APAH
[38]. This evolution towards autoimmunity might be based on the
apparent relation between the BMPR2 and the differentiation and mat-
uration of the T lymphocytes in the thymus [39, 40], where mutations
in this gene may interfere in the normal development of thymocytes
[39]. This was also suggested to explain the presence of connective
tissue diseases in APAH [41].
When we separated the GD patients group into carriers and non-
carriers of the variant, we found slightly increased values of BMPR2
expression in the carriers, but not statistically significant. In addition,
the protein expressed in the LCLs of both groups matched the pre-
dicted molecular weight of 115 kD. It would be necessary to analyse
a great number of samples in order to confirm these expression
differences.
The TGF-b/BMP signalization pathway is one of the most impor-
tant routes for cell stability making its presence ubiquitous within the
organism. Its influence may vary between cell types because of the
existing cell receptors and the context of hormones and growth fac-
tors [42, 43], but its main roles remain being the regulation of cell
proliferation, differentiation, apoptosis and development. On the one
hand, TGF-b can appear in three isoforms (TGF-b1, TGF-b2 and TGF-
b3) with TGF-b1 being the most studied [44]. The TGF-b1 binds to
the TGF-b type 2 receptor, and after its activation, it binds to the TGF-
b type 1 receptor and phosphorylates it in the serine/threonine
residues. Then, by the union of two receptors of each type, an hetero-
complex with activity activin-like kinase is formed that will phospho-
rylate the Smad 2/3 proteins, which will then be able to translocate
towards the nucleus to regulate gene expression [45]. This gene reg-
ulative effect can be also caused without the need of phosphorylation
by the activation of the Smad 4.
On the other hand, the BMP signalization starts when BMP binds
to the BMPR2, which as a serine/threonine kinase protein phosphory-
lates one of the BMP type 1 receptors (ALK-3/BMPR-IA, ALK-6/
BMPR-IB or ALK-2) forming a heterocomplex [46]. Upon its activa-
tion, the type 1 receptor activates and phosphorylates the Smad 1/5/8
proteins [47], which will then bind to the Smad 4 protein and translo-
cate to the nucleus to regulate gene expression. The Smad 4 protein
is therefore common in both pathways playing a central role. There
has been reported that when BMPR2 signalization through the Smads
proteins decrease, TGF-b signalization increases, and this effect is the
result of their competition for the usage of the Smad 4 protein [48].
However, there is evidence of a more complex reciprocal regulation
for both pathways [49]. Thus, the increased BMPR2 expression we
found in our study could be paired with a decrease in the expression
of the TGF-b1, something that has been demonstrated for patients
with GD in a recent study carried out in biopsy samples from thyroid
pathology patients [50].
TGF-b1 has been widely related to cell proliferation and tumour
repression in thyroid healthy tissue, but it is believed to have the oppo-
site function in cancerous thyroid [45, 51–54]. Thus, the different types
of thyroid neoplasia show varying levels of the TGF-b1. In our case, all
the patients with GD presented goitre, five diffuse and two nodular, so
we could hypothesize that the goitre could be caused by the dysregula-
tion of the TGF-b/BMP signalling pathway. BMPR2 overexpression
should be confirmed in thyroid tissue. Although, the role of the TGF-b1
pathway has been extensively analysed in the thyroid gland, scarce
studies have referred to the role of BMPR2 in this tissue.
The unanswered question is still why this variant appears in
high frequency in patients with GD. We could consider a founder
effect as a plausible explanation. However, we could neither rule
out the possibility of this variant acting as an enhancer, affecting
gene expression of a completely unrelated gene located within the
chromosome 2. This enhancer activity has been reported with
molecular distances of up to 1 Mbp [55]. Theoretically, a single
base pair change as the reported in the c.419-19delT could make
the enhancer miss its target, altering gene expression and affecting
carrier’s phenotype.
Chromosome 2 has a wide variety of genes, but we would like to
suggest a couple of candidates to be modulated by this possible
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enhancer. Because of its proximity to the BMPR2 gene, the CTLA4
gene and the cluster of differentiation 28 (CD28; OMIM # 186760)
would be suitable choices as they both are located in the q.33 posi-
tion. CTLA4 and CD28 are homologous proteins that bind to the B7
proteins [56]. CTLA4 acts as a checkpoint in the immune response,
transmitting an inhibitory signal to T cells and down-regulating
immune responses, whereas CD28 (UNIPROT #10747) plays the con-
trary role, transmitting a stimulatory signal [57]. Also, CTLA4 has
already been widely linked with GD [31, 58–60], so the possibility of
an enhancer modulating its expression or its counterpart’s is interest-
ing, as it could possibly alter GD development. A misbalance between
CTLA4 and CD28 could mean that T cells would be activating B cells
in a higher ratio, being the presence of anti-TSHR antibodies the
cause of GD, this augmented antibody production could affect GD
development and evolution.
The main limitation of our study is the low number of samples
included in the molecular analysis, as it diminishes our ability to draw
robust conclusions. Besides, we could not perform a genotype–
phenotype correlation to verify whether the c.419-43delT variant or
the differences in BMPR2 genetic expression affect patients’ pheno-
type. However, the comprehensive genetic analysis performed and
the strength of some findings add value to our results.
To conclude, the c.419-19delT appears in high frequency in
patients with GD, and it does not produce alterations in the splicing
process in the tested cell lines, although it should be checked in thy-
roid and vascular endothelial cells due to the high variable behaviour
of the spliceosome between tissues. The BMPR2 gene is overex-
pressed in patients with GD, some articles referred decreased expres-
sion of TGF-b1 in GD patients’ thyroid, and this could be explained by
Smad 4 protein competition between the TGF-b/BMP signalization
routes. Thus, BMPR2 should be taken into consideration as a possible
therapeutic target for GD novel treatments.
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